Literature DB >> 3008994

Anti-neurofilament antibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome.

S E Kornguth, T Kalinke, G B Grunwald, H Schutta, D Dahl.   

Abstract

The sera of patients with small cell carcinoma of the lung (SCCL) and an associated visual paraneoplastic syndrome (VPNS) have high titer immunoglobulins that react with retinal ganglion cells and with cloned lines of the SCCL. The immunoglobulins in the sera of two patients with SCCL and VPNS reacted with at least one common antigen shared by neural cells and cloned lines of the SCCL. The molecular weights of the predominant neural and tumor antigens were 205,000, 145,000, 65,000, and 20,000-24,000 as determined by Western blots. Three of the antigens from neural tissue copurify and comigrate electrophoretically with neurofilament proteins. Polyclonal antibodies prepared against authentic neurofilament proteins react with antigens having molecular weights identical to those of proteins that react with immunoglobulins from the SCCL-VPNS patients. Polyclonal antibodies that were prepared against isolated retinal ganglion cells and that were shown previously to cause the immunoablation of the ganglion cells in vivo reacted most intensely with the Mr 205,000 antigen and weakly with the Mr 145,000 and Mr 70,000 antigens. Treatment of the Western blots with alkaline phosphatase from Escherichia coli did not affect the immunoreactivity between the immunoglobulins and the purified neurofilament proteins. It is proposed that the immunoglobulins in the sera of patients with SCCL-VPNS may be involved etiologically in the development of the VPNS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008994

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Autoantibodies to photoreceptor membrane proteins and outer plexiform layer in patients with cancer-associated retinopathy.

Authors:  R Peek; B G Dijkstra; B Meek; R W A M Kuijpers
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

Review 2.  Paraneoplastic syndromes: a role for the immune system.

Authors:  J P Antel; R Moumdjian
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

3.  Antineuronal antibodies in small cell lung carcinoma--a significance for paraneoplastic syndromes?

Authors:  W Grisold; M Drlicek; W Popp; K Jellinger
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

4.  Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer.

Authors:  Grazyna Adamus
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-03-09       Impact factor: 4.799

5.  Anti-CNS antibodies in neurological and psychiatric disorders.

Authors:  N E Anderson; J B Posner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

6.  Reactivity of circulating antineuronal antibodies (CANA) on peripheral nervous system structures.

Authors:  W Grisold; M Drlicek; U Liszka; K Jellinger; W Popp
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

7.  Severe course of cutaneous melanoma associated paraneoplastic retinopathy.

Authors:  U Kellner; N Bornfeld; M H Foerster
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

8.  Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients.

Authors:  G M Elrington; N M Murray; S G Spiro; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

9.  Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis.

Authors:  D F Rosberger; S L Tshering; B Polsky; M H Heinemann; R F Klein; S Cunningham-Rundles
Journal:  Clin Diagn Lab Immunol       Date:  1994-07

10.  Electrophysiological findings in paraneoplastic retinopathy.

Authors:  Y Matsui; M C Mehta; O Katsumi; S E Brodie; T Hirose
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.